Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab + Anti-platelet Therapy in HNSCC
NCT03245489Phase 1Completed
- Sponsor
- Medical University of South Carolina
- Start
- Mar 2018
- Primary completion
- Nov 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Medical University of South Carolina. Primary endpoint: Effect of Pembro + antiplatelet on major cellular parameters at 12 weeks. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03245489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03245489.